A controlled study of danazol for the treatment of karyotypically normal spontaneous premature ovarian failure

James N. Anasti, Lorene M. Kimzey, Ruby Defensor, Beverly J. White, Lawrence M. Nelson
In: Fertility and Sterility · 1994 · vol. 62(4) , pp. 726–730 · doi:10.1016/s0015-0282(16)56996-9 · PMID:7926080 · W2419297781
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-11 ⓘ

This controlled study investigated the efficacy of danazol in treating karyotypically normal spontaneous premature ovarian failure.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo determine if the immunomodulatory and gonadotropin-suppressing properties of danazol would improve follicle function or ovulation rates in patients with karyotypically normal spontaneous premature ovarian failure.DesignProspective, double-blind, crossover trial.SettingTertiary care research institution.InterventionsTwo intervention phases lasting 4 months each: one phase during which patients received a standardized estrogen and progestin replacement regimen and one phase during which each patient received a twice daily 400 mg oral dose of danazol.PatientsFifty-two patients with karyotypically normal spontaneous premature ovarian failure ranging in age from 21 to 39 years.Main outcome measuresWe measured serum E2 and P levels weekly during the 2 months after each intervention. We defined a serum E2 > 50 pg/mL (184 pmol/L) as evidence of ovarian follicle function and a P > 3.0 ng/mL (9.5 nmol/L) as evidence for ovulation.ResultsOf the 46 patients who completed the study, danazol did not significantly enhance ovarian follicle function or the chance of ovulation. Eight patients ovulated after danazol and four patients ovulated after estrogen and progestin. The power to detect a 30% and a 5% ovulation success rate with therapy was 0.80 and 0.90, respectively. Overall, 30 of 46 women (65%) demonstrated ovarian follicle function and 10 women (21%) ovulated.ConclusionWe were unable to demonstrate a statistically significant benefit from the immunomodulatory and gonadotropin-suppressing effects of danazol in patients with karyotypically normal spontaneous premature ovarian failure. These patients often have spontaneous remission. Thus, controlled studies are required to determine the effectiveness of treatments for this condition.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-13T18:37:28.025090+00:00
License: CC0 · commercial use OK